Amikacin in gram-negative paediatric infections

Area of Science:

• Pediatric Infectious Diseases
• Antimicrobial Therapy
• Gram-Negative Infections

Background:

• Gram-negative bacterial infections pose significant risks in pediatric populations.
• Effective and safe antimicrobial agents are crucial for treating severe pediatric infections.

Purpose of the Study:

• To evaluate the efficacy and safety of amikacin in treating Gram-negative infections in children.
• To determine cure rates for amikacin therapy across different infection sites.

Main Methods:

• A study involving sixty-six children aged two days to thirteen years.
• Treatment with amikacin for various Gram-negative infections, including severe and moderate cases.
• Assessment of clinical and bacteriological cure rates post-treatment.

Main Results:

• Amikacin achieved a high overall cure rate of 92% (82% complete, 10% partial) in sixty-six pediatric patients.
• Excellent efficacy was observed in urinary/gastro-intestinal (95% cure) and skin/soft tissue infections (94% cure).
• A 75% cure rate was noted for respiratory tract infections.

Conclusions:

• Amikacin demonstrates significant efficacy in treating a broad spectrum of Gram-negative bacterial infections in children.
• The drug is a valuable therapeutic option for severe pediatric infections, with favorable outcomes across multiple infection sites.
• High cure rates support the continued use of amikacin in pediatric infectious disease management.